VXUS vs EFA: returns, risk and drawdowns compared
Vanguard Total International Stock ETF against iShares MSCI EAFE ETF, over the same 15 years (February 2011 to November 2026) with dividends reinvested.
Data updated November 2026
VXUS
Vanguard Total International Stock ETF
10,000 became
25,478
- A year on average
- +6.1%
- Annual volatility
- 14.9%
- Deepest fall
- −27.8%
- Worst month
- −16.3%
EFA
iShares MSCI EAFE ETF
10,000 became
27,247
- A year on average
- +6.5%
- Annual volatility
- 14.8%
- Deepest fall
- −27.6%
- Worst month
- −14.1%
EFA came out ahead by 0.5 percentage points a year from February 2011 to November 2026. VXUS swung more (14.9% against 14.8% a year). The correlation of monthly returns was 0.98: they moved almost in lockstep.
Growth of 10,000: VXUS vs EFA
Who was ahead, and when
The gap between the two over the previous three years, at each month-end. Above zero VXUS had returned more, below zero EFA. VXUS was ahead in 52% of the 155 three-year periods.
Annualised 3-year return of VXUS minus that of EFA, in percentage points a year.
Falls from the previous high
Month-end values. Deepest fall: VXUS −27.8%, EFA −27.6%.
All the figures
| VXUS | EFA | |
|---|---|---|
| Annual return (CAGR) | +6.1% | +6.5% |
| Total return | +155% | +172% |
| Annual volatility | 14.9% | 14.8% |
| Deepest fall (month-end) | −27.8% | −27.6% |
| Worst month | −16.3% | −14.1% |
| Best month | +13.0% | +14.3% |
| Positive months | 58% | 61% |
| Best year | 2025: +32.4% | 2025: +31.6% |
| Worst year | 2022: −16.1% | 2022: −14.3% |
| 1-year return | +11.1% | +11.5% |
| 5 years, a year | +7.3% | +8.0% |
| 10 years, a year | +9.0% | +9.1% |
| Trading currency | USD | USD |
First nine rows: the same 190 months for both funds. Trailing returns: to each fund’s last close.
Year by year
Full calendar years both funds were trading. The higher of the two each year is in bold.
Holding both: half VXUS, half EFA
| VXUS alone | EFA alone | 50/50 | |
|---|---|---|---|
| A year on average | +6.1% | +6.5% | +6.3% |
| Annual volatility | 14.9% | 14.8% | 14.8% |
| Deepest fall (month-end) | −27.8% | −27.6% | −27.7% |
| Worst month | −16.3% | −14.1% | −15.2% |
With a correlation of 0.98 the mix behaved almost like either fund alone: its volatility of 14.8% sits between the two. Rebalanced to 50/50 every month, before costs.
Questions
Which has returned more, VXUS or EFA?
From February 2011 to November 2026, VXUS returned +6.1% a year and EFA +6.5% a year, with dividends reinvested. Over rolling 3-year periods VXUS did better in 52% of cases. Past returns do not predict future returns.
Which is riskier, VXUS or EFA?
Over the same months annual volatility was 14.9% for VXUS and 14.8% for EFA; the deepest fall from a month-end high was 27.8% and 27.6%, and the worst single month −16.3% and −14.1%.
How correlated are VXUS and EFA?
The correlation of their monthly returns was 0.98: they moved almost in lockstep. Holding both adds little diversification compared with holding one.
What about holding both VXUS and EFA?
Half in each, rebalanced every month, returned +6.3% a year over the same period, with 14.8% annual volatility and a deepest month-end fall of 27.7%.
More comparisons
- VXUS — Vanguard Total International Stock ETFReturns, drawdowns and risk
- EFA — iShares MSCI EAFE ETFReturns, drawdowns and risk
- VXUS vs VEA
- VXUS vs IEFA
- VTI vs VXUS
- VEA vs EFA
- IEFA vs EFA
- Portfolio backtesting, explainedRebalancing, costs and attribution
- Alternatives to Portfolio Visualizer, comparedWhich tool fits which job
How the figures are calculated
Total return in the fund’s trading currency, from end-of-day prices with dividends reinvested on the ex-date. The fund’s own ongoing charges are already reflected in its price; trading costs, taxes and currency conversion are not included. Past returns do not predict future returns.
The comparison uses only the months in which both funds have prices, so the figures cover the same period even when one fund is older.
Source: MarketStack end-of-day prices, total return with dividends reinvested. Figures are historical and descriptive; they are not forecasts and not investment advice. MEDGE Capital does not recommend buying or selling any instrument. Risk disclaimer.